Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Spermidine is being marketed as a memory booster, heart protector, and anti-aging supplement — but the science hasn't caught up. Despite promising animal studies and intriguing observational data, the largest human trial found no significant cognitive benefit. Experts say there's currently no solid basis to recommend spermidine supplements for disease prevention or treatment.
Spermidine, a naturally occurring polyamine found in wheat germ, legumes, mushrooms, and aged cheeses, has been generating buzz in the longevity space. Proponents claim it can protect memory, support cardiovascular health, and even extend life — largely by triggering autophagy, the cellular "recycling" process. Animal studies have shown promising results, and observational data hint at an inverse link between spermidine intake and mortality. But the clinical evidence in humans remains limited.
The most rigorous trial to date — the 12-month SmartAge RCT involving 100 older adults with subjective cognitive decline — found no significant improvement in memory or any secondary outcomes, including executive function, quality of life, sleep, or cardiovascular markers. A small 2025 pilot study did show some favorable shifts in autophagy and inflammatory biomarkers, but with only 12 participants over 56 days, it's far too early to draw clinical conclusions.
Key Takeaways:
Why it matters: With the supplement industry aggressively marketing spermidine to aging populations, clinicians need to be equipped to counsel patients accurately. The current evidence simply does not support supplementation recommendations — though the science is worth watching.